Zole IT SB 130mg Capsule contains Itraconazole 130mg, a broad-spectrum triazole antifungal agent used for the treatment of various fungal infections. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the synthesis of ergosterol, a key component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. Zole IT SB is indicated for the management of systemic and superficial mycoses, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. It is particularly effective against infections caused by dermatophytes, yeasts, and dimorphic fungi. The capsule formulation ensures optimal bioavailability when taken with food, promoting adequate absorption and therapeutic plasma concentrations. Dosage and duration of therapy should be individualized based on the type and severity of infection, as well as patient response. Common adverse effects may include gastrointestinal disturbances, headache, and rash, while rare but serious hepatotoxicity necessitates periodic liver function monitoring during prolonged therapy. Caution is advised in patients with hepatic impairment and those receiving concomitant medications metabolized via the cytochrome P450 system due to potential drug interactions. Zole IT SB 130mg Capsule should be used under medical supervision to ensure safe and effective antifungal treatment.